Dallas, TX – Aug 27, 2019 — OTC PR WIRE — Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced the company will publish a scheduled analyst report covering the company’s recent biopharmaceutical cannabis extract business development updates after market today. The analyst report update initiative was triggered by KALY’s recent CEO update on the company’s cannabis extract biopharmaceutical business pursuing $170 billion in pharmaceutical treatments where the CEO announced new patent and trademark applications on KALY’s CBD Formulation for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The report will include coverage on the impact of the company’s recently announced CBD extraction contracts with hemp farming operations worth $15 million, and the company’s recently posted 2019 YTD financials reporting 250% revenue growth. The analyst report will also address KALY’s ongoing business partnership with Puration, Inc. (USOTC: PURA) and the sales of KALY’s Hemp4mula CBD candy line through North American Cannabis Holdings, Inc’s (USOTC: USMJ) ecommerce site www.usmj.com.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company’s actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.